Walter Karolin, Rodriguez-Aznar Eva, Ferreira Monica S Ventura, Frappart Pierre-Olivier, Dittrich Tabea, Tiwary Kanishka, Meessen Sabine, Lerma Laura, Daiss Nora, Schulte Lucas-Alexander, Najafova Zeynab, Arnold Frank, Usachov Valentyn, Azoitei Ninel, Erkan Mert, Lechel Andre, Brümmendorf Tim H, Seufferlein Thomas, Kleger Alexander, Tabarés Enrique, Günes Cagatay, Johnsen Steven A, Beier Fabian, Sainz Bruno, Hermann Patrick C
Department of Internal Medicine I, University Medical Centre Ulm, 89081 Ulm, Germany.
Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital of the RWTH Aachen, 52062 Aachen, Germany.
Cancers (Basel). 2021 Jun 23;13(13):3145. doi: 10.3390/cancers13133145.
To assess the role of telomerase activity and telomere length in pancreatic CSCs we used different CSC enrichment methods (CD133, ALDH, sphere formation) in primary patient-derived pancreatic cancer cells. We show that CSCs have higher telomerase activity and longer telomeres than bulk tumor cells. Inhibition of telomerase activity, using genetic knockdown or pharmacological inhibitor (BIBR1532), resulted in CSC marker depletion, abrogation of sphere formation in vitro and reduced tumorigenicity in vivo. Furthermore, we identify a positive feedback loop between stemness factors (NANOG, OCT3/4, SOX2, KLF4) and telomerase, which is essential for the self-renewal of CSCs. Disruption of the balance between telomerase activity and stemness factors eliminates CSCs via induction of DNA damage and apoptosis in primary patient-derived pancreatic cancer samples, opening future perspectives to avoid CSC-driven tumor relapse. In the present study, we demonstrate that telomerase regulation is critical for the "stemness" maintenance in pancreatic CSCs and examine the effects of telomerase inhibition as a potential treatment option of pancreatic cancer. This may significantly promote our understanding of PDAC tumor biology and may result in improved treatment for pancreatic cancer patients.
为了评估端粒酶活性和端粒长度在胰腺癌症干细胞中的作用,我们在原发性患者来源的胰腺癌细胞中使用了不同的癌症干细胞富集方法(CD133、醛脱氢酶、成球培养)。我们发现,癌症干细胞比肿瘤整体细胞具有更高的端粒酶活性和更长的端粒。使用基因敲低或药物抑制剂(BIBR1532)抑制端粒酶活性,会导致癌症干细胞标志物减少、体外成球能力丧失以及体内致瘤性降低。此外,我们发现干性因子(NANOG、OCT3/4、SOX2、KLF4)和端粒酶之间存在正反馈回路,这对癌症干细胞的自我更新至关重要。在原发性患者来源的胰腺癌样本中,端粒酶活性和干性因子之间平衡的破坏会通过诱导DNA损伤和凋亡来消除癌症干细胞,为避免癌症干细胞驱动的肿瘤复发开辟了新的前景。在本研究中,我们证明端粒酶调节对于胰腺癌症干细胞“干性”的维持至关重要,并研究了端粒酶抑制作为胰腺癌潜在治疗选择的效果。这可能会显著促进我们对胰腺导管腺癌肿瘤生物学的理解,并可能改善胰腺癌患者的治疗效果。